These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 6175122

  • 21. [The objective of medical treatment: relieve the symptoms or stop the course?].
    Desgrandchamps F.
    Ann Urol (Paris); 2006 Mar; 40 Spec No 1():14-6. PubMed ID: 16649585
    [No Abstract] [Full Text] [Related]

  • 22. [Urination disorders caused by prostatic hyperplasia. Effect of Bazoton, Harzol and Prosta-capsules].
    Hallwachs O.
    MMW Munch Med Wochenschr; 1981 Oct 30; 123(44):1675-6. PubMed ID: 6171728
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. [Experience in the use of doxazosin in patients with benign hyperplasia of the prostate].
    Lopatkin NA, Loran OB, Pushkar' DIu, Perepanova TS, Tevlin KP.
    Urol Nefrol (Mosk); 1998 Oct 30; (3):3-5. PubMed ID: 9644978
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. [Conservative therapy of prostatic hyperplasia with urinary retention].
    Djulepa J.
    Med Welt; 1983 Dec 02; 34(48):1377-9. PubMed ID: 6197601
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. [Uroselectivity of alpha-1 antagonism in the treatment of benign prostatic hypertrophy: on the pharmacologic concept of the clinical approach].
    Jolliet P, Bourin M.
    Therapie; 1998 Dec 02; 53(1):61-6. PubMed ID: 9773101
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Urodynamic and clinical effects of terazosin therapy in symptomatic patients with and without bladder outlet obstruction: a stratified analysis.
    Witjes WP, Rosier PF, Caris CT, Debruyne FM, de la Rosette JJ.
    Urology; 1997 Feb 02; 49(2):197-205; discussion 205-6. PubMed ID: 9037281
    [Abstract] [Full Text] [Related]

  • 35. Commentary on tolterodine for men with benign prostatic hyperplasia and lower urinary tract symptoms.
    O'Leary MP.
    J Urol; 2008 May 02; 179(5 Suppl):S86. PubMed ID: 18405764
    [No Abstract] [Full Text] [Related]

  • 36. The urodynamic assessment of benign prostatic hyperplasia obstruction.
    Artibani W.
    J Urol (Paris); 1995 May 02; 101(1):42-4. PubMed ID: 7545728
    [No Abstract] [Full Text] [Related]

  • 37. [Proscar (finasteride, MSD) in the treatment of patients with prostatic hyperplasia].
    Pytel' IuA, Vinarov AZ.
    Urol Nefrol (Mosk); 1996 May 02; (4):25-7. PubMed ID: 8928344
    [Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. [Controlled study of the effects of Pygeum africanum extract on the functional symptoms of prostatic adenoma].
    Dufour B, Choquenet C, Revol M, Faure G, Jorest R.
    Ann Urol (Paris); 1984 May 02; 18(3):193-5. PubMed ID: 6084978
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.